Agenus to Participate in Webcast Hosted by William Blair on AGEN1181 and Balstilimab AACR Presentations
April 06 2021 - 8:30AM
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive
pipeline of checkpoint antibodies, cell therapies, adjuvants, and
vaccines designed to activate immune response to cancers and
infections, today announced that Dr. Jennifer Buell, President and
COO, Dr. Steven O’Day, Chief Medical Officer, and Dr. Dhan Chand,
Scientific Director, Head of Drug Discovery, at Agenus, will
participate in a webcast hosted by Dr. Matt Phipps of William Blair
on Saturday, April 10, 2021 at 10:30 a.m. ET.
Dr. Steven O’Day will review abstracts presented
at AACR 2021 featuring AGEN1181 and balstilimab, including
objective responses observed in the ongoing Phase 1/2 trial,
clinical benefits seen in underserved patient populations, and how
they may inform the path forward for continued development.
Dr. Jennifer Buell and Dr. Dhan Chand will also
be available to discuss the Fc-engineering driving AGEN1181’s
enhanced activity, and how the AACR presentations support
AGEN1181’s place in the Agenus pipeline, alone and in combination
with other immune-focused anti-cancer mechanisms.
Registration for the webinar can be done in advance
at
https://williamblair.zoom.us/webinar/register/WN_4tTw7GEFQPC2qC4B3TzrfQ.
A replay will be available after the call on the
Events & Presentations page of the Agenus website at
https://investor.agenusbio.com/events-and-presentations.
About AgenusAgenus is a
clinical-stage immuno-oncology company focused on the discovery and
development of therapies that engage the body's immune system to
fight cancer. The Company's vision is to expand the patient
populations benefiting from cancer immunotherapy by pursuing
combination approaches that leverage a broad repertoire of antibody
therapeutics, adoptive cell therapies (through its AgenTus
Therapeutics subsidiary), and proprietary cancer vaccine platforms.
The Company is equipped with a suite of antibody discovery
platforms and a state-of-the-art GMP manufacturing facility with
the capacity to support clinical programs. Agenus is headquartered
in Lexington, MA. For more information, please visit
www.agenusbio.com and our Twitter handle @agenus_bio. Information
that may be important to investors will be routinely posted on our
website and Twitter.
Forward-Looking StatementsThis
press release contains forward-looking statements that are made
pursuant to the safe harbor provisions of the federal securities
laws, including statements regarding clinical development plans and
timelines, the therapeutic potential of AGEN1181 alone and in
combination with other agents, as well as the anticipated
presentation of updated clinical and preclinical data. These
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, among others, the factors described
under the Risk Factors section of our most recent Quarterly Report
on Form 10-Q or Annual Report on Form 10-K filed with the
Securities and Exchange Commission. Agenus cautions investors not
to place considerable reliance on the forward-looking statements
contained in this release. These statements speak only as of the
date of this press release, and Agenus undertakes no obligation to
update or revise the statements, other than to the extent required
by law. All forward-looking statements are expressly qualified in
their entirety by this cautionary statement.
ContactAgenus Investor
RelationsJan Medina,
CFAAgenus781-674-4490Jan.Medina@agenusbio.com
Agenus Media RelationsKimberly
HaKKH Advisors917-291-5744kimberly.ha@kkhadvisors.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From May 2024 to Jun 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2023 to Jun 2024